当前位置： SCI文献检索 > Cancer Discovery期刊下所有文献 > Tweaking Transcription to Stop AML Cell Growth.

Tweaking Transcription to Stop AML Cell Growth.

Abstract：

:A new compound with anti-leukemia activity perturbs gene transcription by modulating super-enhancer activity.

journal_name

Cancer Discov

journal_title

Cancer discovery

authors

doi

10.1158/2159-8290.CD-NB2015-149

subject

Has Abstract

pub_date

2015-12-01 00:00:00

pages

OF1

issue

12

eissn

2159-8274

issn

2159-8290

pii

2159-8290.CD-NB2015-149

journal_volume

5

pub_type

新闻

相关文献

Cancer Discovery文献大全
  • Blood Monocyte Frequency May Be a Biomarker for Response to Anti-PD-1.

    abstract：:CD14+CD16-HLA-DRhi monocyte frequency was linked to response to anti-PD-1 in patients with melanoma. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2018-016

    authors：

    更新日期：2018-03-01 00:00:00

  • RIF1 operates downstream of 53BP1 to block homologous recombination.

    abstract：:53BP1 requires RIF1 to block 5' end resection required for homologous recombination. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2013-015

    authors：

    更新日期：2013-03-01 00:00:00

  • ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.

    abstract：UNLABELLED:ARID1A, SWI/SNF chromatin remodeling complex subunit, is a recently identified tumor suppressor that is mutated in a broad spectrum of human cancers. Thus, it is of fundamental clinical importance to understand its molecular functions and determine whether ARID1A deficiency can be exploited therapeutically. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-14-0849

    authors： Shen J,Peng Y,Wei L,Zhang W,Yang L,Lan L,Kapoor P,Ju Z,Mo Q,Shih IeM,Uray IP,Wu X,Brown PH,Shen X,Mills GB,Peng G

    更新日期：2015-07-01 00:00:00

  • Fish Reveal Origins of Melanoma.

    abstract：:A new study of zebrafish may explain why only certain skin cells grow into tumors. Besides melanoma-promoting mutations, these cells express key neural crest genes, such as crestin and sox10, that induce regression to an embryonic state. They also bear epigenetic changes that might amplify expression of these genes. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2016-019

    authors： Leslie M

    更新日期：2016-04-01 00:00:00

  • Dual Checkpoint Blockade Takes Aim at Relapsed Mesothelioma.

    abstract：:In the largest clinical trial to date of immune checkpoint inhibitors for mesothelioma, patients treated with nivolumab-either alone or in combination with ipilimumab-posted impressive response rates and survival outcomes, according to data presented at the 2017 American Society of Clinical Oncology Annual Meeting. Ho...

    journal_title：Cancer discovery

    pub_type： 临床试验,杂志文章

    doi：10.1158/2159-8290.CD-NB2017-087

    authors：

    更新日期：2017-08-01 00:00:00

  • Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

    abstract：:Clinically relevant subtypes exist for pancreatic ductal adenocarcinoma (PDAC), but molecular characterization is not yet standard in clinical care. We implemented a biopsy protocol to perform time-sensitive whole-exome sequencing and RNA sequencing for patients with advanced PDAC. Therapeutically relevant genomic alt...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-18-0275

    authors： Aguirre AJ,Nowak JA,Camarda ND,Moffitt RA,Ghazani AA,Hazar-Rethinam M,Raghavan S,Kim J,Brais LK,Ragon D,Welch MW,Reilly E,McCabe D,Marini L,Anderka K,Helvie K,Oliver N,Babic A,Da Silva A,Nadres B,Van Seventer EE,

    更新日期：2018-09-01 00:00:00

  • Antibody Improves Survival in Gastric Cancer.

    abstract：:Results from a randomized phase II study indicate that adding the experimental antibody IMAB362, which targets the tight junction protein claudin18.2, to standard chemotherapy is more effective than chemotherapy alone in previously untreated patients with advanced gastric cancer. IMAB362 extended progression-free and ...

    journal_title：Cancer discovery

    pub_type：

    doi：10.1158/2159-8290.CD-NB2016-077

    authors：

    更新日期：2016-08-01 00:00:00

  • ADC Could Benefit Some with Breast Cancer.

    abstract：:Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A phase III trial is under way to compare its safety and efficacy with that of standard chemotherapy. ...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-034

    authors：

    更新日期：2019-05-01 00:00:00

  • Cancer "Clock" Opens New Therapeutic Avenues.

    abstract：:Long ignored, the importance of circadian rhythms-the focus of this year's Nobel Prize in Physiology or Medicine-is beginning to gain attention from researchers interested in cancer prevention, drug discovery, and therapeutic optimization. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-149

    authors：

    更新日期：2017-12-01 00:00:00

  • Targeting the Noncoding Genome: Superenhancers Meet Their Kryptonite.

    abstract：: In this study, McKeown and colleagues carried out a genome-wide characterization and stratification of the enhancer landscape in acute myeloid leukemia (AML). The authors' analysis led to the discovery of a novel RARA superenhancer found in a subset of patients with AML, rendering these leukemia cells highly sens...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0860

    authors： Wang E,Aifantis I

    更新日期：2017-10-01 00:00:00

  • Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset.

    abstract：UNLABELLED:Identifying genetic alterations that prime a cancer cell to respond to a particular therapeutic agent can facilitate the development of precision cancer medicines. Cancer cell-line (CCL) profiling of small-molecule sensitivity has emerged as an unbiased method to assess the relationships between genetic or c...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-15-0235

    authors： Seashore-Ludlow B,Rees MG,Cheah JH,Cokol M,Price EV,Coletti ME,Jones V,Bodycombe NE,Soule CK,Gould J,Alexander B,Li A,Montgomery P,Wawer MJ,Kuru N,Kotz JD,Hon CS,Munoz B,Liefeld T,Dančík V,Bittker JA,Palmer M,

    更新日期：2015-11-01 00:00:00

  • YY1 Facilitates Enhancer-Promoter Contacts to Promote Gene Expression.

    abstract：:YY1 preferentially occupies active enhancers and promoters and forms dimers to promote DNA looping. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2017-233

    authors：

    更新日期：2018-02-01 00:00:00

  • Insights into Epigenetic Remodeling in VHL-Deficient Clear Cell Renal Cell Carcinoma.

    abstract：: Clear cell renal cell carcinoma (ccRCC) is characterized by loss of the von Hippel-Lindau tumor suppressor gene (VHL), and the functional tumorigenic consequences of this loss have been used to develop therapies for advanced ccRCC, such as targeting activation of the HIF pathway. Yao and colleagues elucidate how ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0971

    authors： Ricketts CJ,Linehan WM

    更新日期：2017-11-01 00:00:00

  • Granule Neuron Precursor-Derived Astrocytes Promote Medulloblastoma.

    abstract：:Granule neuron precursors transdifferentiate into astrocytes in the tumor microenvironment. ...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-RW2020-016

    authors：

    更新日期：2020-03-01 00:00:00

  • Seeking value as cancer drug costs soar.

    abstract：:As significant increases in the costs of cancer drugs cause financial difficulties for many U.S. patients, some oncologists suggest that changes in pricing policies at the federal and state levels are inevitable. ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-ND2013-018

    authors： Bender E

    更新日期：2013-08-01 00:00:00

  • Brain May Prime Metastatic Cell Growth.

    abstract：:Metastasizing tumor cells lose expression of the tumor suppressor PTEN at a much higher rate when they enter the brain compared to other organs, suggesting that the brain's unique microenvironment may prime metastatic cells for aggressive growth, a recent study reports. The findings may have implications for developin...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB2015-163

    authors：

    更新日期：2016-01-01 00:00:00

  • Triple-acting drug boosts prostate cancer survival.

    abstract：:A phase III trial of the agent MDV3100 in men with advanced prostate cancer previously treated with docetaxel-based chemotherapy is being stopped early so that the drug can be given to all participants. ...

    journal_title：Cancer discovery

    pub_type： 新闻

    doi：10.1158/2159-8290.CD-NB111711OL-09

    authors：

    更新日期：2011-12-01 00:00:00

  • Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes.

    abstract：:Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases under 4 years of age, and carried out histologic review, methylation profiling, and custom panel, g...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-19-1030

    authors： Clarke M,Mackay A,Ismer B,Pickles JC,Tatevossian RG,Newman S,Bale TA,Stoler I,Izquierdo E,Temelso S,Carvalho DM,Molinari V,Burford A,Howell L,Virasami A,Fairchild AR,Avery A,Chalker J,Kristiansen M,Haupfear K,Dalt

    更新日期：2020-07-01 00:00:00

  • Enzalutamide Bests Older NSAAs in mHSPC.

    abstract：:According to results from ENZAMET, a global phase III trial, adding enzalutamide to standard treatment for men with metastatic hormone-sensitive prostate cancer is superior in prolonging survival compared with older nonsteroidal antiandrogen drugs. ...

    journal_title：Cancer discovery

    pub_type： 评论,新闻

    doi：10.1158/2159-8290.CD-NB2019-066

    authors：

    更新日期：2019-08-01 00:00:00

  • Second-generation ALK inhibitors: filling the non "MET" gap.

    abstract：:Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provi...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-14-0410

    authors： Ramalingam SS,Khuri FR

    更新日期：2014-06-01 00:00:00

  • PI3K and STAT3: a new alliance.

    abstract：UNLABELLED:Recent proteomic data have uncovered an interdependence of PI3K and STAT3. In PI3K-tranformed murine cells, STAT3 is phosphorylated on Y705 and activated in a PI3K-dependent manner. Dominant negative STAT3 interferes with PI3K-induced oncogenic transformation. Phosphorylation of STAT3 in PI3K-transformed mur...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-11-0218

    authors： Vogt PK,Hart JR

    更新日期：2011-11-01 00:00:00

  • Panel OKs CAR T Therapy for Leukemia.

    abstract：:An expert panel recommended approval of Novartis's experimental chimeric antigen T-cell therapy, tisagenlecleucel, for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia. The therapy would be the first of its kind approved for cancer and has the potential to transform standard of...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-108

    authors：

    更新日期：2017-09-01 00:00:00

  • Gilead Buys into Tizona's Anti-HLA-G Strategy.

    abstract：:Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona's investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical tria...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2020-077

    authors：

    更新日期：2020-10-01 00:00:00

  • Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.

    abstract：: In this issue Grommes and colleagues elegantly show that the irreversible inhibitor of Bruton tyrosine kinase, ibrutinib, promotes a high proportion of durable responses in primary central nervous system lymphoma, a type of diffuse large B-cell lymphoma (DLBCL), and also in secondary DLBCL relapsing to the centra...

    journal_title：Cancer discovery

    pub_type： 评论,杂志文章

    doi：10.1158/2159-8290.CD-17-0714

    authors： Lakshmanan A,Byrd JC

    更新日期：2017-09-01 00:00:00

  • Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer.

    abstract：UNLABELLED:As parallel advances in cancer biology and drug development continue to elevate the role of targeted therapies in oncology, the need for imaging biomarkers that systematically measure the biology associated with therapeutic intervention has become more urgent. Although the molecular imaging community has a c...

    journal_title：Cancer discovery

    pub_type： 杂志文章,评审

    doi：10.1158/2159-8290.CD-12-0178

    authors： Evans MJ

    更新日期：2012-11-01 00:00:00

  • Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.

    abstract：:We performed cytosine methylation sequencing on genetically diverse patients with acute myeloid leukemia (AML) and found leukemic DNA methylation patterning is primarily driven by nonpromoter regulatory elements and CpG shores. Enhancers displayed stronger differential methylation than promoters, consisting predominan...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-16-1032

    authors： Glass JL,Hassane D,Wouters BJ,Kunimoto H,Avellino R,Garrett-Bakelman FE,Guryanova OA,Bowman R,Redlich S,Intlekofer AM,Meydan C,Qin T,Fall M,Alonso A,Guzman ML,Valk PJM,Thompson CB,Levine R,Elemento O,Delwel R,Meln

    更新日期：2017-08-01 00:00:00

  • Lower Airway Dysbiosis Affects Lung Cancer Progression.

    abstract：:In lung cancer, enrichment of the lower airway microbiota with oral commensals commonly occurs, and ex vivo models support that some of these bacteria can trigger host transcriptomic signatures associated with carcinogenesis. Here, we show that this lower airway dysbiotic signature was more prevalent in the stage IIIB...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-20-0263

    authors： Tsay JJ,Wu BG,Sulaiman I,Gershner K,Schluger R,Li Y,Yie TA,Meyn P,Olsen E,Perez L,Franca B,Carpenito J,Iizumi T,El-Ashmawy M,Badri M,Morton JT,Shen N,He L,Michaud G,Rafeq S,Bessich JL,Smith RL,Sauthoff H,Fel

    更新日期：2020-11-11 00:00:00

  • Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target.

    abstract：:In this issue of Cancer Discovery, Dominguez and colleagues identify diacylglycerol kinase alpha (DGKα), an enzyme that converts the membrane lipid diacylglycerol to phosphatidic acid, as a central node upstream of mTOR and other oncogenic pathways. Importantly, targeting DGKα causes apoptosis in cancer cells and tumo...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0244

    authors： Bhat KP,Aldape K

    更新日期：2013-07-01 00:00:00

  • Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.

    abstract：UNLABELLED:Next-generation sequencing was used to identify Notch mutations in a large collection of diverse solid tumors. NOTCH1 and NOTCH2 rearrangements leading to constitutive receptor activation were confined to triple-negative breast cancers (TNBC; 6 of 66 tumors). TNBC cell lines with NOTCH1 rearrangements associ...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-13-0830

    authors： Stoeck A,Lejnine S,Truong A,Pan L,Wang H,Zang C,Yuan J,Ware C,MacLean J,Garrett-Engele PW,Kluk M,Laskey J,Haines BB,Moskaluk C,Zawel L,Fawell S,Gilliland G,Zhang T,Kremer BE,Knoechel B,Bernstein BE,Pear WS,Liu

    更新日期：2014-10-01 00:00:00

  • Global Cost of Smoking Passes $1 Trillion.

    abstract：:A new report from the World Health Organization and the NCI estimates that the worldwide cost of smoking-due to health problems and lost productivity-exceeds $1 trillion annually, with the biggest economic burden falling on low- and middle- income countries. That's because proven interventions, such as tax and price i...

    journal_title：Cancer discovery

    pub_type： 杂志文章

    doi：10.1158/2159-8290.CD-NB2017-014

    authors：

    更新日期：2017-03-01 00:00:00